In This Section
Back to Grantees
Loading...
Illuminating metabolism: A pioneering approach to combat pancreatic cancer

Illuminating metabolism: A pioneering approach to combat pancreatic cancer

Costas Lyssiotis, PhD, received the 2013 Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant, 2016 AACR-Bayer Innovation and Discovery Award, and 2017 AACR NextGen Grant for Transformative Cancer Research. Dr. Lyssiotis shares how these three AACR grants helped him and his team discover several mechanisms by which metabolites support tumor growth, immune evasion, and resistance to therapy in pancreatic cancer.

Celebrating 30 Years of Impact Across the Globe

Celebrating 30 Years of Impact Across the Globe

As we continue our celebration of 30 years of impact of the AACR Research Grants Program, we share how recipient of a 2022 Victoria’s Secret Global Fund for Women’s Cancers Career Development Award, in partnership with Pelotonia and the AACR, Chemtai Mungo, MD, MPH is seeking to make a difference in the lives of women from low and middle-income countries.

Celebrating 30 Years of Impact: From AACR Grant to AACR Award 

Celebrating 30 Years of Impact: From AACR Grant to AACR Award 

As we continue our celebration of 30 years of impact of the AACR Research Grants Program, we feature recipient of the 2022 Award for Outstanding Achievement in Basic Cancer Research, Dr. Christina Curtis. Dr. Curtis shares the impact of her AACR Triple-Negative Breast Cancer (TNBC) Foundation / Carol’s Crusade for a Cure Foundation Career Development Award on her research.

Leveraging TTFields for Residual Glioblastoma Disease

Leveraging TTFields for Residual Glioblastoma Disease

Sara G.M. Piccirillo, PhD, was inspired to study glioblastoma whilst an undergraduate student at the National Carlo Besta Neurological Institute in her hometown of Milan, Italy. Now an assistant professor at the University of New Mexico Health Sciences Center, Dr. Piccirillo, was awarded the AACR-Novocure Tumor Treating Fields (TTFields) Research Grant in 2021 to investigate the impact of TTFields on residual glioblastoma disease.